Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Dramine Expectorant
- Development stage
- Unknown
- Lead developer
- National Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
N-Dramine Expectorant is an approved over-the-counter (OTC) combination expectorant and antihistamine liquid formulation developed and manufactured by National Pharmaceutical. It is indicated for the symptomatic relief of cough and congestion associated with colds, allergies, or upper respiratory tract conditions. The formulation contains four active ingredients: diphenhydramine (a first-generation H1 histamine receptor antagonist with antihistamine and antitussive properties), ammonium chloride (an expectorant that increases respiratory tract secretions to loosen mucus), sodium citrate (a buffering agent and expectorant), and menthol (a topical analgesic and cooling agent that soothes the throat and airways). It is administered orally as a syrup.
- Brand names
- NA-DRAMINE EXPECTORANTNA-DRAMINE EXPECTORANT (BROWN)NA-DRAMINE EXPECTORANT (RED)
- Other names
- ammonium chloride + diphenhydramine + menthol + sodium citrate
02
Targets
HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on N-Dramine Expectorant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-Dramine Expectorant.